We have observed
13 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Method for preparation of a high concentration liquid formulation of an antibody
Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions
Vent gases for use in drying, storing and/or reconstituting biomolecules
NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES
NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS
NOVEL EP2 RECEPTOR AGONISTS
METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY
FORMULATION OF AN ANTIBODY AND USE THEREOF
DEVICE AND SYSTEM FOR DELIVERY OF AN AEROSOL TO A PATIENT ON VENTILATORY SUPPORT
TREATMENT OF PARTLY CONTROLLED OR UNCONTROLLED SEVERE ASTHMA WITH A PDE4 INHIBITOR (AND IN COMBINATION WITH A LEUKOTRIENE MODIFIER)
UTI FUSION PROTEINS
PDE4 INHIBITOR FOR THE TREATMENT OF DIABETIC NEPHROPATHY